← Back to search

Vir Biotechnology Inc

VIR · NASDAQ

Research and Development in Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

ESG Scores

Overall ESG
4.3
Environmental
4.6
Social
3.7
Governance
5.0

Gender Diversity

Female Directors0.3636%
Female Executives0.5417607223476298%
CEO GenderFemale